Navigation Links
Medivation Reports Year-End 2007 Financial Results and Pipeline Progress
Date:2/19/2008

ing for 2006.

Total operating expenses increased to $33.8 million for the year ended December 31, 2007, from $16.1 million for the same period in 2006.

Medivation ended 2007 with $43.3 million in cash and equivalents, plus a remaining capacity of $78.8 million under its committed equity line of credit facility. The Company expects total operating expenses in 2008 to increase significantly beyond 2007 levels, due primarily to further expansion of Dimebon and MDV3100 development, including the upcoming confirmatory pivotal Phase 3 trial of Dimebon in AD and the expanded dosing groups in the ongoing Phase 1-2 trial of MDV3100 in HRPC.

2008 Corporate Milestones

"In 2008, we plan to begin multiple AD clinical trials for Dimebon, including our confirmatory pivotal Phase 3 trial. We also look forward to presenting a steady stream of data across all of our programs in 2008 -- including top-line results from our ongoing Phase 2 trials in Huntington's disease and hormone-refractory prostate cancer," continued Dr. Hung.

During 2008 Medivation intends to:

-- Initiate a second, confirmatory pivotal Phase 3 trial of Dimebon in AD

in the second quarter with the goal of completing the trial and

applying for U.S. and European marketing approval in 2010.

-- Conduct multiple clinical trials of Dimebon in AD for marketing and

reimbursement purposes and to provide a safety database of

approximately 1,500 patients as part of its marketing application. In

the second quarter of 2008, the Company plans to begin the first of

these trials -- a 20 patient Phase 1 trial to evaluate the safety and

tolerability of Dimebon when given to AD patients who are also taking

Aricept(R), the leading AD treatment on the market.

-- Complete the ongoing Phase 2 study of Dimebon in Huntington's disease

in the second quarter.

-- Begin global Phase 3 clinical studie
'/>"/>

SOURCE Medivation, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Medivation Announces Participation in Acumen BioFin Rodman & Renshaw 9th Annual Healthcare Conference
2. Medivation Selected as Founding Member of New NASDAQ(R) NeuroInsights(R) Neurotech Index
3. United Therapeutics Reports Fourth Quarter and Annual 2007 Financial Results
4. Favrille Reports Fourth Quarter and Year End 2007 Financial Results
5. JADO Reports Clinical Proof of Concept With Raft Modulator in Atopic Dermatitis
6. OrbusNeichs Genous(TM) Bio-Engineered R Stent(TM) is Feasible in Acute Myocardial Infarction Patients, American Heart Journal Paper Reports
7. Senesco Technologies Reports Second Quarter Fiscal 2008 Financial Results
8. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
9. Escalon(R) Reports Second Quarter Fiscal 2008 Results
10. CV Therapeutics Reports Option Grants Under Nasdaq Marketplace Rule 4350
11. Eklin Medical Reports Record Revenues for 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... Knowledgent , the data and analytics ... potential of big data analytics in the life sciences ... help life sciences and healthcare organizations understand the ways ... business insights. , The life sciences and healthcare industries ... patient profiling, compliance and regulatory requirements, and scientific research. ...
(Date:5/21/2015)... SQI Diagnostics Inc. ("SQI" or the "Company") (TSX-V: SQD; ... proprietary technologies and products for advanced microarray diagnostics, today ... fiscal quarter ended March 31, 2015. ... with our existing customers and to develop new opportunities," ... SQI. "The delivery of a fully automated sqidlite™ system ...
(Date:5/21/2015)... 21, 2015 Specialty Pharmacy Times ... been admitted to BPA Worldwide as a business ... track audience data for Specialty Pharmacy Times based ... “By becoming a member of BPA Worldwide, Specialty ... our clients with the most reliable, unequaled data,” ...
(Date:5/21/2015)... May 21, 2015  Prima Biomed Ltd. (NASDAQ: ... striving to become a leader in the development of ... that the final CVac data from the Phase II ... trend for a clinically meaningful improvement in Overall Survival ... patients. In the group of second remission ...
Breaking Biology Technology:New White Paper Explores the Potential of Big Data Analytics in Life Sciences and Healthcare 2SQI Diagnostics Reports Second Quarter Financial Results 2SQI Diagnostics Reports Second Quarter Financial Results 3SQI Diagnostics Reports Second Quarter Financial Results 4SQI Diagnostics Reports Second Quarter Financial Results 5SQI Diagnostics Reports Second Quarter Financial Results 6SQI Diagnostics Reports Second Quarter Financial Results 7SQI Diagnostics Reports Second Quarter Financial Results 8Specialty Pharmacy Times Joins BPA Worldwide 2Correction Continues after Big Move - BrokerBank Securities, Inc. 2
... Microbia, Inc. today,announced that it has changed ... a long-lived tree that thrives in the harshest ... 1,500 years. Known as a,"nurse tree," it provides ... and more organic matter for birds, reptiles,insects, animals, ...
... the world,s,leading online bioscience job board and life ... Career Fair for Boehringer Ingelheim on May 8,2008 ... at the Sheraton,Boston Hotel from 11 am to ... Boehringer Ingelheim is looking to fill several ...
... for Design Excellence and Patient Ease-of-Use, BROOKFIELD, ... ) today won the 2008 Medical Design Excellence ... device. The Genesis DM won in the,rehabilitation and ... remote patient monitoring device is,ideal for both the ...
Cached Biology Technology:Microbia Announces Name Change to Ironwood Pharmaceuticals 2Boehringer Ingelheim and BioSpace Search for Scientists at Career Fair in Boston, Massachusetts 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 2Honeywell HomMed Wins 2008 Medical Design Excellence Award for Genesis DM Remote Care Device 3
(Date:5/21/2015)... May 21, 2015 According ... Market by Solutions (Hardware, Software, Services), by Applications (Surveillance ... others), by End-Users (Military & Defense & Commercial) ... Thermal Imaging Market is expected to grow from ... 2020, at a Compound Annual Growth Rate (CAGR) ...
(Date:5/19/2015)... 19, 2015  Technology is rapidly advancing, outpacing enterprises, ... the cloud. Passwords and their management are soon to ... standards-based specifications such as those developed by the FIDO ... passwords presents for BYOD, COPE, IoT, and mobile payments, ... protocol. In response to the call ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated ... human interface solutions, today announced the appointment of ... and Chief Financial Officer, reporting to Rick ... Synaptics, current Chief Financial Officer, Kathleen Bayless ... Mr. Ali brings extensive financial ...
Breaking Biology News(10 mins):Thermal Imaging Market Worth $9,998.9 Million by 2020 2Thermal Imaging Market Worth $9,998.9 Million by 2020 3Thermal Imaging Market Worth $9,998.9 Million by 2020 4HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 2HYPR Corp. Biometric Security Integration Kit Shields Applications and Devices Across the Internet of Things 3Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... his landscape is the developing brain - specifically the ... nerve cells. His research at The Montreal Neurological Institute ... the brain as a dynamic landscape where connections between ... of the environment. Dr. Ruthazer is the winner of ...
... 2011 (Rome, Italy) -- Researchers presenting late breaking research ... Conference on HIV Pathogenesis, Treatment and Prevention (IAS 2011) have ... pre-exposure prophylaxis (PrEP) and antiretroviral treatment. The IAS 2011 ... community leaders since Sunday in Rome. ...
... FASEB MARC (Minority Access to Research Careers) Program has ... for Leukocyte Biology (SLB) Meeting in Kansas City, MO ... to promote the entry of underrepresented minority students, postdoctorates ... community and to encourage the participation of young scientists ...
Cached Biology News:No room for inaccuracy in the brain 2No room for inaccuracy in the brain 3No room for inaccuracy in the brain 4First global study of real-world circumcision rollout conducted over 3-year period in South Africa amongst 110,000 adults shows a marked reduction (>60 percent) of HIV acquisition among circumcised adult men 2First global study of real-world circumcision rollout conducted over 3-year period in South Africa amongst 110,000 adults shows a marked reduction (>60 percent) of HIV acquisition among circumcised adult men 3First global study of real-world circumcision rollout conducted over 3-year period in South Africa amongst 110,000 adults shows a marked reduction (>60 percent) of HIV acquisition among circumcised adult men 4
RABBIT ANTI PARATHION...
Similar to proteasome (prosome, macropain) 26S subunit, ATPase, 1 Antigen: Recombinant Protein...
Homo sapiens HCLS1 associated protein X-1 Antigen: Recombinant Protein...
Amino Acid Analysis is performed using ion-exchange separation of the amino acids from acid hydrolysates, followed by ninhydrin detection. Typical quantities required are 0.1 to 0.5 mg, depending on...
Biology Products: